Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. Bone Marrow Transplant 2016 Apr;51(4):617-8
Date
01/05/2016Pubmed ID
26726940DOI
10.1038/bmt.2015.295Scopus ID
2-s2.0-84953295752 (requires institutional sign-in at Scopus site) 19 CitationsAuthor List
Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LCAuthors
Ehab L. Atallah MD Professor in the Medicine department at Medical College of WisconsinKaren-Sue B. Carlson MD, PhD Associate Professor in the Medicine department at Medical College of Wisconsin
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin
Laura Michaelis MD Chief, Professor in the Medicine department at Medical College of Wisconsin
Marcelo C. Pasquini MD, MS Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AllograftsFemale
Hematologic Neoplasms
Hematopoietic Stem Cell Transplantation
Humans
Male
Middle Aged
Nitriles
Primary Myelofibrosis
Pyrazoles
Pyrimidines